Cadempino-based Zambon Biotech has signed an exclusive licensing agreement with Amneal Pharmaceuticals, a company located in the U.S. federal state of New Jersey. The agreement relates to the IPX203 medication, a novel oral formulation of Carbidopa/Levadopa, a combined drug for the treatment of Parkinson’s disease.
According to a press release, the formulation is currently under review by the U.S. Food and Drug Administration. Zambon will apply for regulatory approval in Europe and market IPX203 in the EU, the UK and Switzerland. Financial details were not disclosed.
“We believe IPX203 can improve the lives of the more than 10 million people worldwide living with Parkinson’s disease,” say Amneal CEOs Chirag and Chintu Patel. Zambon Biotech CEO Frank Weber adds: “Given our group’s capabilities in commercialization and our existing footprint in neurology, particularly Parkinson’s, we are pleased to partner with Amneal to bring IPX203 to Parkinson’s patients in Europe.”
Zambon has had a location in Ticino, Switzerland, since the early 1960s. This is a subsidiary of the multinational Zambon Group, which is headquartered in Besso near Milan. According to the company, Zambon Schweiz AG has significant strategic importance within the Group, acting as a production center of the most important medications for other Group subsidiaries and for third parties in Europe, the U.S. and Asia. Over 30 medications and around 75 packaging and dosing systems are produced and marketed in Switzerland. The export share of the overall production is 90 per cent. ce/mm
Related news
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com